Drugs / BC-U001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04971980 | Apr 2021 → Jul 2023 overdue | rheumatoid arthritis | Beijing Baylx Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC-U001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971980 ↗ |
| Modality | Cell therapy | “human umbilical cord-derived mesenchymal stem cell product” NCT04971980 ↗ |
| Route | Intravenous | “intravenously administered” NCT04971980 ↗ |